Abstract
Background: Previous studies have found suboptimal control of symptom burden to be widespread among patients with asthma and COPD. Recently, new delivery devices for inhaled treatments have been developed to address inhaler misuse.
Aims/Objectives: To assess asthma disease control and COPD symptom burden in patients treated with an FDC of inhaled corticosteroids (ICS) and long-acting beta agonists (LABA).
Methods: The Phase IV SPRINT study was conducted in 10 European countries. Asthma and COPD patients were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers including DuoResp® Spiromax®. Data were obtained over a 3-month period, during a single routine physician’s office visit. Physician-assessed disease severity was recorded. Asthma control was defined as Asthma Control Test (ACT) score > 19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score < 10 defining low COPD symptom burden.
Results: 1,101 asthma and 560 COPD patients were included. Of these, 13% of asthma patients and 42% of COPD patients had severe or very severe disease. Among patients using any ICS/LABA FDC, 62% of asthma patients met the threshold for disease control and 16% of COPD patients had low symptom burden. Among patients using DuoResp Spiromax, these rates were 66% and 16%, respectively.
Conclusions: More than half of asthma patients using any ICS/LABA FDC inhaler met the threshold for asthma control. Comparatively few patients met the pre-defined criterion for low COPD symptom burden, as expected in a chronic disease with an overall more severely affected patient population.
Aims/Objectives: To assess asthma disease control and COPD symptom burden in patients treated with an FDC of inhaled corticosteroids (ICS) and long-acting beta agonists (LABA).
Methods: The Phase IV SPRINT study was conducted in 10 European countries. Asthma and COPD patients were receiving treatment with an FDC of ICS/LABA, delivered via various inhalers including DuoResp® Spiromax®. Data were obtained over a 3-month period, during a single routine physician’s office visit. Physician-assessed disease severity was recorded. Asthma control was defined as Asthma Control Test (ACT) score > 19. COPD symptom burden was assessed by COPD Assessment Test (CAT), with a CAT score < 10 defining low COPD symptom burden.
Results: 1,101 asthma and 560 COPD patients were included. Of these, 13% of asthma patients and 42% of COPD patients had severe or very severe disease. Among patients using any ICS/LABA FDC, 62% of asthma patients met the threshold for disease control and 16% of COPD patients had low symptom burden. Among patients using DuoResp Spiromax, these rates were 66% and 16%, respectively.
Conclusions: More than half of asthma patients using any ICS/LABA FDC inhaler met the threshold for asthma control. Comparatively few patients met the pre-defined criterion for low COPD symptom burden, as expected in a chronic disease with an overall more severely affected patient population.
| Original language | Spanish |
|---|---|
| Pages (from-to) | 1006 |
| Number of pages | 1 |
| Journal | European Respiratory Journal |
| Volume | 52 |
| Issue number | 62 |
| DOIs | |
| Publication status | Published - 15 Sept 2018 |